Immune Induction Strategies to Improve Response to Immune Checkpoint Blockade in Triple Negative Breast Cancer (TNBC) Patients

NCT04159818 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

52

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer

Interventions

DRUG: Nivolumab
DRUG: Cisplatin
DRUG: Low dose doxorubicin

Sponsor

The Netherlands Cancer Institute

Collaborators

[object Object]